Is this you?
Request access for Southeast Regional Research Group with your @clinicaltrialsgps.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Southeast Regional Research Group
Unclaimed profileSite Network · Savannah, GA · ~3 sites
Intera lens
ICP 5Lift (cardio sample) 0.57Recruit soph 0.43
Quality Scorecard (1–100)
Overall87Recruit75Ops93Sponsor87Ther96
Performance (observed)
Historical trials
680
Completed
371
Terminated/Withdrawn
66
Completion rate
85%
Active now
227
Phase 2
249
Phase 3
377
Realized enrollment
841,452
First study year
1984
Years active
41
Match confidence
high
Enrollment velocity (inf)
20,523
Therapeutic
Areas
Multi-therapeutic: Hypertension, Chronic Pain, Diabetes, COPD, and others
Specialties
Multi-specialty research: skin infections, infectious diseases, general research
Breadth (conditions)
1,605
Languages
English
States
GA
Recruitment (web observed)
Trial Finder
Yes
Patient database
Y
Advertises recruitment
Yes
Capability notes
Multi-site coordination across Savannah, Rincon, and Columbus; hospital and clinic partnerships; comprehensive ancillary services
Relationships
Sponsors
National Cancer Institute (NCI); Alliance for Clinical Trials in Oncology; SWOG Cancer Research Network; Radiation Therapy Oncology Group; ECOG-ACRIN Cancer Research Group; NRG Oncology
CROs
Fortrea; IQVIA Pty Ltd; PPD, Part of Thermo Fisher Scientific; Parexel; Premier Research; The Emmes Company, LLC
Partnerships
Columbus Regional Healthcare System (40% ownership partnership)
Owner / parent
Unknown
Acquisitions
Acquired 40% ownership stake by Columbus Regional Healthcare
Expansion
Yes (partnership with Columbus Regional, expansion to campus planned)
Capacity & people
Investigators
—
Coordinators
—
CEO
Unknown
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
NewTrials@SERRG.com
Tech & DCT
Builds tech
Unknown
Home visits
N
DCT / decentralized
N
Tech stack
Unknown
Recruiting visible
Y
Notes
Three-site network in Georgia with multi-therapeutic focus; established relationships with hospitals and clinics; Phase II-IV capability; regional scope; moderate Intera fit—limited geographic footprint and modest scale but growing.
Recommendation features (sample indication)
Ind fit 1.00Liftability 0.57Overall87
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.